Seven days in medicine: 2-8 September 2020BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3486 (Published 10 September 2020) Cite this as: BMJ 2020;370:m3486
Risks to younger school children are minimal
Preliminary results from Public Health England’s Covid-19 Surveillance in School KIDs (sKIDs) study found that, of 12 026 adults and children tested for covid-19 in 131 English primary and preschools in June and early July, just one child and two adults were positive—0.02% of those who were swabbed. They also showed no evidence of onward transmission to household contacts or in schools. Antibody rates in staff and students varied by region but reflected levels detected in the general population.
Russia’s Sputnik V vaccine shows promise
No serious adverse events were detected in two small, early phase trials of the Russian Sputnik V vaccine among 76 people aged 18 to 60 who were followed for 42 days, Russian researchers reported in the Lancet.1 Participants received the frozen or freeze dried version of either one dose or two doses (21 days apart) of the two part vaccine composed of recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S). Mild side effects included pain at injection site (58%), hyperthermia (50%), headache (42%), asthenia (28%), and muscle and joint pain (24%). Antibody responses were detected in all participants within 21 days.
US agency CDC says vaccine is coming soon
The US Centers for Disease Control and Prevention told public health departments in all 50 states and five large cities to get ready to distribute a covid-19 vaccine by 1 November, two days before the US presidential election. Two …